ストックスクリーナーアプリを入手
23.24
5.25%
1.16
アフターアワーズ：
23.22
-0.02
-0.09%
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
Syndax Pharmaceuticals holds steady as investors await a fresh catalyst - AD HOC NEWS
SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals (NASDAQ:SNDX) Draws Fresh Market Attention - Kalkine Media
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates? - Insider Monkey
Purchase/sale of business (net) of Syndax Pharmaceuticals Inc – SWB:1T3 - TradingView
Price to sales forward of Syndax Pharmaceuticals Inc – MUN:1T3 - TradingView
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Enterprise value to revenue forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Does Syndax Pharmaceuticals’ (SNDX) Russell Value Index Exit Quietly Recast Its Liquidity And Risk Narrative? - simplywall.st
Enterprise value to EBITDA forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Trading the Move, Not the Narrative: (SNDX) Edition - Stock Traders Daily
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Price to earnings forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Price to earnings forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Enterprise value to revenue forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Price to book forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Price to sales forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Price to book forward of Syndax Pharmaceuticals Inc – MUN:1T3 - TradingView
Syndax Pharmaceuticals Inc Actuals & Estimates (DUS:1T3) - TradingView
SNDX Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
1T3 Forecast — Price Target — Prediction for 2027 - TradingView
Syndax Pharmaceuticals (SNDX) Stock Could Be 51.9% Undervalued After SAVE Trial Data - Sahm
Syndax Pharmaceuticals Inc (SNDX) Institutional Confidence - TradingKey
Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Syndax Pharmaceuticals StockLong-term cancer strategy under investor scrutiny - AD HOC NEWS
Is Strong SAVE Trial Data Altering The Investment Case For Syndax Pharmaceuticals (SNDX)? - Sahm
Elmind Capital LP Purchases New Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Catalio Capital Management LP - MarketBeat
Eversept Partners LP Decreases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Syndax Pharmaceuticals Inc - TradingKey
Apis Capital Advisors LLC Acquires 86,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Syndax Pharmaceuticals stock gains test resistance near $19.68 after EHA congress participation - Traders Union
(SNDX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Syndax Pharmaceuticals Inc (SNDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Syndax Pharmaceuticals Inc (SNDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Syndax Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Syndax Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Eventide Asset Management LLC Has $26.01 Million Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (SNDX) Stock Valuation After Positive SAVE Trial Data In High-Risk Leukemia - Sahm
Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial DataWhat's Changed - Yahoo Finance
Voss Capital LP Buys Shares of 125,000 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Rhenman & Partners Asset Management AB Sells 87,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options - Stock Titan
SNDX (NASDAQ) Rule 144 notice: Director-linked sale of 31,235 shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
[144] Syndax Pharmaceuticals Inc SEC Filing - Stock Titan
Syndax showcases revuforj (revumenib) data at EHA 2026 - grafa.com
Syndax (SNDX) Reveals Encouraging Results from SAVE Trial for AM - GuruFocus
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced (NASDAQ:SNDX) - Seeking Alpha
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 - The Manila Times
Leukemia drug revumenib shows up to 97% remission in EHA 2026 data - Stock Titan
Syndax Pharmaceuticals Announces Publication of Save Data on Revuforj in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML - marketscreener.com
SNDX6417984 Bond Coupon Analysis — Rate & Payments - TradingView
Syndax Shareholders Approve 2026 Equity and ESPP Plans - The Globe and Mail
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):